Recent advances in cancer treatment have significantly boosted survival rates and improved patient outcomes. Because of these promising developments, the high costs associated with innovative therapies pose a major challenge. Experts warn that the financial burden of cancer care in the United States is projected to soar to an alarming $245 billion by 2030, up from $185 billion today, according to a study published in Cancer Epidemiology, Biomarkers & Prevention , raising urgent questions about healthcare affordability and access for

patients nationwide.

Monique Gary, D.O., M.Sc., chief medical officer of Sure Inc., the maker of Bexa, a breast cancer detection device, notes that balancing the high costs of cutting-edge cancer therapies with ensuring equitable access for diverse patient

See Full Page